RxSight (RXST) Q1 2026 Earnings Transcript

RxSight reported Q1 revenue of $30.9 million, down 18% year over year, as lower LDD sales offset stable LAL unit volume. Gross margin improved to 76.1% from 74.8%, but SG&A rose 11% to $31.9 million, contributing to a net loss of $15.9 million, or $0.38 per share. Management reiterated 2026 revenue guidance of $120 million to $135 million, kept gross margin guidance at 70%-72%, and raised operating expense expectations to the high end of the $150 million to $160 million range due to continued commercial investment and international expansion.

Analysis

The key read-through is that RXST is no longer a pure install-base growth story; it has become a utilization-recovery story with operating leverage delayed by deliberate commercial spending. That matters because the business can look “stable” on unit trends while still producing disappointing earnings power if management keeps leaning into field expansion before the installed base converts. The market is likely underestimating how sensitive the equity is to the cadence of LAL utilization improvements versus the slower, lower-visibility LDD placement cycle.

The second-order winner is not RXST’s hardware base, but any adjacent premium-IOL leaders that benefit from category expansion without shouldering the same workflow burden. If management is right that premium cataract penetration keeps expanding, the real battleground is share of surgeon mindshare, not device count; that favors larger incumbents with broader sales coverage and easier bundling, while pressuring smaller premium offerings that lack a differentiated post-op adjustment workflow. The more RXST spends to educate and reengage, the more it validates that adoption friction remains real and operationally expensive.

The biggest risk is that the current stabilization proves to be a plateau rather than an inflection. With gross margin stepping down into the back half and OpEx held at the high end, any slip in sequential utilization would compress narrative and valuation quickly over the next 1-2 quarters. Conversely, if the company shows even modest acceleration in Q2/Q3, the stock can rerate sharply because the setup is highly consensus-sensitive and underwrites a 2027 operating leverage story.

The contrarian angle is that management’s measured tone is probably more credible than bulls want to admit: this is not a demand-collapse recovery, it’s a slow education-and-workflow rebuild across a large installed base. That means upside likely comes in a longer, lumpier path than the market wants, with the best entry probably after any near-term disappointment tied to gross margin or operating losses rather than chasing strength into the print.

Key Decisions for Investors

• Avoid initiating a full-size long in RXST immediately; wait for a Q2/Q3 utilization inflection. Risk/reward improves only if sequential LAL volumes reaccelerate, because current guidance already prices in gradual improvement.
• For tactical longs, buy RXST only on post-earnings weakness tied to gross margin or OpEx concerns, using a 3-6 month horizon. The setup is asymmetric if management confirms utilization stabilization plus rising field conversion, but downside is meaningful if growth remains flat.
• Consider a pair trade: long JNJ vs short RXST for 1-2 quarters. If premium IOL category growth persists but RXST’s workflow-heavy model slows conversion, larger diversified incumbents should capture share with lower execution risk.
• Use RXST Jan-2027 call spreads rather than common stock if expressing a 2027 recovery thesis. This limits capital at risk while keeping exposure to the likely catalyst window when international revenue and workflow innovations can matter.
• Set a stop-loss discipline below the next guidance update if LAL growth fails to improve sequentially. The thesis breaks if utilization plateaus, because the stock then becomes a cash-burn story with no near-term margin lever.